The Promise of PP2A. Discovering novel therapeutics for the treatment of neurodegenerative disorders.

Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. LEARN MORE ABOUT SIGNUM

Signum Biosciences spin out Signum Dermalogix, is focused on developing new and innovative dermatological products with a commitment to quality, efficacy and safety.
LEARN MORE ABOUT SIGNUM DERMALOGIX

Signum Biosciences spin out Signum Nutralogix is dedicated to developing innovative dietary supplements for enhancing brain health.                                                                  LEARN MORE ABOUT SIGNUM NUTRALOGIX